Benefits & Risks of Peptide Therapeutics for Physical & Mental Health
What this covers
Huberman surveys the major classes of therapeutic peptides now in use for tissue repair, muscle growth, mood enhancement, and longevity, explaining how each works at the cellular level and what evidence supports or limits their use. The episode maps four primary peptide categories—BPC-157, growth hormone secretagogues, epithalon, and melanocortin agonists—along with emerging options like kisspeptin. Huberman's central claim is that peptides are potent, pleiotropic compounds whose real risks remain obscured by an evidence base built almost entirely on animal studies and user reports rather than human clinical trials, and that treatment requires physician oversight, clean sourcing, and realistic assumptions about safety.
The episode distinguishes peptide categories by mechanism and evidence tier. Growth hormone secretagogues split into two types: GHRH-mimicking peptides like sermorelin and tesamorelin, which have human trial data and FDA approval for specific indications, versus ghrelin-mimicking peptides like hexarelin and MK-677, which are more potent but increase hunger, cortisol, and prolactin and carry desensitization risk. BPC-157 exemplifies the evidence gap—decades of peer-reviewed animal work showing tissue repair through angiogenesis, yet no credible human trials and thus no way to rule out placebo. The discussion of sourcing and side effects turns especially cautionary: peptides from gray or black markets often carry lipopolysaccharide contamination; combining different peptides requires careful dosing to avoid redundant pathway activation; and augmenting growth factors and angiogenesis carries real tumor and cancer growth risk that receives little public attention, particularly when BPC-157 is stacked with growth-hormone-raising compounds. The episode also covers dosing protocols, cycling schedules, routes of administration, and which peptides require the most physician monitoring, framing the field as early-stage despite its rapid expansion.
Huberman argues that therapeutic peptides like BPC-157, growth hormone secretagogues, epithalon, and melanocortin agonists work through pleiotropic mechanisms backed largely by animal data and anecdote, so users should treat them as potent, risk-bearing compounds requiring physician oversight and clean sourcing rather than assuming they are safe because they aren't hormones.
- Peptides have pleiotropic (many-target) effects, so any desired benefit comes bundled with unintended pathway activation and risk
- The evidence base for most therapeutic peptides is overwhelmingly animal studies plus anecdote, with almost no human clinical trials
- Augmenting growth factors and angiogenesis carries a real tumor/cancer growth risk that is under-discussed
This asset isn't compiled yet
You're seeing its claims, ranked. Compile it to build the argument threads, weight them, and check each claim against your library — the full view.
Most peptides, especially therapeutic peptides, have pleiotropic effects, meaning a single peptide activates many different cellular pathways and affects many cell types and organ systems depending on cell type, time of day, and downstream effects, so there is no way to obtain a targeted single-pathway effect without activating other pathways.
“always, always, always, if you take peptides, especially therapeutic peptides, designed to promote activity within a given pathway for a specific purpose, you are going to activate other pathways as well. There's simply no way to remove the pleiotropic feature of peptide therapeutics.”
The melanotan peptides (1 through 5) all mimic melanocyte-stimulating hormone and cause skin darkening, but melanotan 1 does not cross the blood-brain barrier (only tanning), whereas melanotan 2-5 cross it and additionally increase mood and libido and decrease appetite; PT-141 (the FDA-approved drug Vyleesi) targets this system and is approved for premenopausal hypoactive sexual desire in women but is used off-label in men.
“melanotan 1 does not cross the blood-brain barrier. It does however stimulate the melanocytes of the skin... Melanotan 2 3 4 and 5 also lead to darkening of the skin... but because they can cross the blood-brain barrier they cause effects that are at the level of psychology”
The melanocortin system links light exposure (UVB sunlight to eyes or skin) through the hypothalamus and pituitary to release of melanocyte-stimulating hormone, causing skin pigmentation while in parallel stimulating dopamine release; this conserved system explains why people and animals feel better, have more energy/libido, and (in animals) darken pelage and breed when sunlight increases in spring.
“There's also a pathway whereby the light stimulates the melanocyte-stimulating hormone system, and in parallel stimulates the release of dopamine.”
Despite a large peer-reviewed animal literature dating back to about 1993, there is essentially no human clinical trial data on BPC-157 (only one poor self-report study), so it is impossible to rule out that its widely reported benefits are robust placebo effects, even though anecdotal reports from hundreds of thousands to millions of users are unusually strong.
“To my knowledge, there is only one study on humans, and it's not a clinical trial, and frankly, it's not the best performed study”
Growth hormone secretagogue peptides fall into two categories: 'type one' GHRH-mimicking peptides (sermorelin, tesamorelin, CJC-1295) which are mostly human-tested and in several cases FDA-approved, and 'type two' growth-hormone-releasing peptides (ipamorelin, hexarelin, GHRP-2/3/6, MK-677) which act by mimicking or stimulating ghrelin and thus also increase hunger and anxiety.
“These peptides encourage the release of growth hormone, but they do so either by mimicking or stimulating the release of another peptide called ghrelin.”
Lipopolysaccharide (LPS) can accumulate during peptide manufacturing and causes an immune response; while a tiny amount may not cause a massive response, repeated exposures accumulate and become problematic, which is why properly cleaned (LPS-removed) peptides from pharma or compounding pharmacies are safer than gray/black-market sources.
“The reason is that LPS causes an immune response. And while a tiny amount of LPS might not cause a massive immune response, the accumulation of many, many LPS exposures can start to become problematic.”
Applied therapeutic peptides fall into three categories: prescription FDA-approved peptides from board-certified physicians (the safest), gray-market peptides purchasable online with questionable safety/efficacy, and black-market peptides which are often contaminated and not what they claim to be; the safest path is prescription peptides because they are cleaned of lipopolysaccharide (LPS).
“There are peptides that are being prescribed by physicians... There are other peptides that reside in kind of a gray market area... And then of course there's the black market peptides.”
Taking growth hormone directly carries common risks including carpal tunnel syndrome, cartilage overgrowth, structural changes to the head, face and body (brow thickening), a lean-but-distended gut, and unusual skin texture; growth-hormone-promoting peptides produce less dramatic structural changes than direct growth hormone.
“When people take growth hormone itself, there are common risks such as carpal tunnel syndrome... There can be active changes in the structure of one's head and face and body.”
Growth hormone secretagogue peptides should be taken about 20-30 minutes before sleep, at least an hour and a half (preferably two hours) after eating and with no food for at least 30 minutes afterward, because elevated blood sugar or food in the gut blunts their growth-hormone- and IGF-1-raising effect, and bedtime timing augments the natural early-night growth hormone pulse.
“Always it's suggested that they be taken at least an hour and a half after eating any food and that you don't eat for at least 30 minutes afterwards because if you happen to have elevated blood sugar or you've got food in your gut, they're not going to have as potent an effect at increasing growth hormone and IGF-1.”
Growth hormone is secreted by the pituitary gland under control of the hypothalamus, is released most heavily during early sleep, and declines by about 15% per decade after age 30; this decline reduces growth hormone's effects on metabolism, fat loss, muscle growth, mood, vitality, and ATP/energy production, motivating interest in augmenting it.
“typically after 30, the amount of growth hormone that's released each night and throughout the day is reduced by about 15% for every decade of life.”
People tend to wrongly assume peptides are inherently safe or free of side effects because they are not hormone therapies like testosterone or estrogen therapy; in fact peptides are very potent compounds with many pleiotropic effects, peptide therapeutics are in early stages, and they carry real risks requiring physician oversight, clean sourcing, regular blood testing, and tumor monitoring.
“people, I think, inadvertently assume that peptides are all safe or innocuous... that because they're not hormone therapies per se, that they are free of side effects and risk.”
Kisspeptin is a recently discovered peptide made in the brain that sits at the top of the reproductive hormone cascade — it turns on GnRH, which triggers LH and FSH release from the pituitary, which in turn stimulate the gonads to produce testosterone and estrogen and drive sperm/follicle development; synthetic kisspeptin is prescribed for hypothalamic amenorrhea and used off-label to boost vitality and libido, while kisspeptin antagonists treat menopausal vasomotor symptoms.
“the signal that turns on GnRH is kisspeptin. Kisspeptin, in other words, is further upstream from GnRH and LSH and FSH. It's a cascade. It goes kisspeptin, GnRH, LH, FSH, testosterone, estrogen.”
Hexarelin is the strongest stimulator of growth hormone release (pulses 2-3x larger than other secretagogues) but can dramatically increase prolactin (suppressing libido), cause fluid retention and malaise, and most problematically desensitize the growth-hormone-releasing-hormone receptors, potentially permanently turning off the system's response to any peptide or endogenous signal.
“Hexarelin can desensitize the receptors for growth hormone-releasing hormone, such that your system will no longer respond either to the Hexarelin or to any other peptide... you could essentially turn off the system permanently.”
Sermorelin (FDA-approved for short stature) and tesamorelin (brand Egrifta, FDA-approved for reducing visceral adiposity in HIV patients) are the most thoroughly tested type-one secretagogues; both increase circulating growth hormone and IGF-1 with both animal and human data, making them more advantageous options than CJC-1295, which had a cardiovascular death in a clinical trial and remains unresolved on safety.
“CJC-1295 has entered clinical trials. There was a death within one of the clinical trials that was related to cardiovascular dysfunction.”
Direct growth hormone injection is subject to negative feedback, where high blood levels cause the pituitary and brain to shut down endogenous growth hormone production; this drove the development of secretagogue peptides that stimulate the body's own growth hormone release by mimicking hypothalamic signals rather than directly supplying growth hormone.
“it is subject to what's called negative feedback. If your blood levels of growth hormone are too high by virtue of injecting growth hormone, well then the pituitary can register that and the brain can register that, and then there's a negative feedback that shuts down growth hormone.”
Thymosin beta 4 (and its truncated synthetic version TB-500) is a peptide naturally produced by the thymus, which is present in children and disappears with age; it promotes tissue repair by stimulating growth of multiple cell types, stem cell proliferation, and extracellular matrix growth, but unlike BPC-157 it is involved in tissue repair, not tissue growth, and does not impact the growth hormone pathway.
“thymosin beta 4 really promotes the growth and infiltration of all sorts of different cell types associated with tissue rejuvenation and especially wound healing and repair. It's been shown to promote stem cell proliferation.”
BPC-157 promotes tissue repair primarily by increasing blood flow to injury sites through angiogenesis: it recognizes injured blood vessels and capillaries and upregulates the enzyme eNOS (endothelial nitric oxide synthase), causing new vasculature to form, which delivers growth factors that further rejuvenate tissue; it also encourages fibroblast migration and growth at the injury site.
“BPC 157 somehow is able to recognize injured blood vessels and injured capillaries and then to promote the activity of a given enzyme called eNOS or endothelial nitric oxide synthase, which then causes more blood vasculature to form at the injury site”
BPC-157 has a very high safety profile in terms of lethal dosing, with an LD50 as high as 2 grams (2,000 mg) per kilogram of body weight; typical therapeutic doses are far lower, around 300-500 micrograms subcutaneously two to three times per week for about 8 weeks, followed by cycling off for 8-10 weeks.
“The LD50 of BPC 157 is incredibly high, okay? It is as high as 2 g, okay? 2 g, 2,000 mg, that is, per kilogram of body weight.”
Epitalon (epithalon) is a synthetic peptide designed to mimic epithalamin, a peptide naturally secreted by the pineal gland (which also produces melatonin); based largely on animal data it is taken as a longevity agent because it appears to suppress tumor growth, increase telomere length, exert anti-inflammatory effects, and recalibrate age-related circadian/melatonin disruptions, though the telomere-longevity link is controversial and no human clinical trials support life extension.
“Epithalon is a peptide that's secreted from the pineal gland... It also makes a peptide called epithalamin... it does appear to be able to adjust telomere length”
Type-two secretagogues like GHRP-3 and MK-677 (an oral, non-injectable GHRP) can potently increase growth hormone but also more than double circulating cortisol and elevate prolactin; because cortisol should be high in the morning and very low at night, and these peptides are taken before bed, the cortisol elevation can be problematic.
“Things like GHRP-3 can potently increase growth hormone, but are known to also potently increase prolactin and cortisol, leading to more than a doubling of circulating cortisol”
BPC-157 is a synthetic peptide manufactured to resemble body protection compound, a peptide that naturally occurs in the gut and is involved in wound healing and repair; its presence in the gut is plausibly linked to the high cellular turnover of gut tissue, which mirrors the cellular turnover involved in wound healing.
“that peptide is BPC, which stands for body protection compound 157. BPC 157 is a synthetic peptide. It's manufactured in a laboratory to resemble a peptide that exists naturally within our gut.”
Combining different growth-hormone-promoting peptides (e.g. sermorelin or tesamorelin with hexarelin, or ipamorelin with CJC-1295) is a legitimate strategy because different amino acid sequences stimulate different modes of action of the same target peptide, but relative dosing must be managed to avoid unnecessary prolactin/cortisol increases and redundant pathway hitting.
“While I'm not opposed to that approach, you just want to make sure that the dosing... of each peptide is such that... you're avoiding unnecessary increases in prolactin and cortisol, and that you're not hitting a pathway redundantly.”
BPC-157 poses a potential tumor growth risk because it upregulates growth hormone receptors and increases VEGF (vascular endothelial growth factor) to drive angiogenesis; tumors thrive on increased blood flow and growth factors, so BPC-157 may maintain or accelerate tumor growth — notably it does the exact opposite of the cancer drug Avastin, which is a VEGF inhibitor.
“if you have a tumor and tumors thrive on increased blood flow because they like to consume growth factors and increased blood flow means increased growth factors... by taking BPC 157 you may be either maintaining or accelerating the growth of a tumor”
Augmenting growth hormone — whether by direct synthetic growth hormone or by secretagogue peptides — increases tumor and cancer risk because growth hormone and IGF-1 are indiscriminate about which tissues they grow, so combining a GH-raising peptide with BPC-157 could potentially increase both the size and vascularization of an existing tumor.
“anytime we augment growth hormone... we are increasing our tumor growth risk and our cancer risk. And that's because growth hormone and IGF-1 are somewhat indiscriminate in terms of the tissues that they promote the growth of.”
In Huberman's own experience taking sermorelin one to two nights per week over a couple of years, it produced very deep early-night sleep but appeared to deplete rapid eye movement sleep (per his Eight Sleep and Whoop trackers), effectively replacing REM with deep sleep, which led him to largely stop taking it because both sleep types serve distinct essential functions.
“it seemed to sort of replace rapid eye movement sleep with more deep sleep. And rapid eye movement sleep is critical for all sorts of things that deep sleep can't achieve and vice versa.”
A peptide is defined as a small protein consisting of short chains of amino acids, strictly two to 50 amino acids, though peptides of 75-100 amino acids are sometimes still considered peptides; combining peptides yields polypeptides, and the order of amino acids along the chain determines what the peptide is and does.
“The basic way that we define a peptide is that it tends to be a small protein, meaning chains of anywhere from two to 50 amino acids.”
Children heal from wounds much faster and with less scarring than adults, which is attributed in part to higher growth hormone, secretions from the thymus (like thymosin beta 4), and other factors; this developmental observation is the rationale underlying both tissue-repair peptides and the logic of taking thymus- and pineal-derived peptides in adulthood.
“it's well known that children recover more quickly from injuries. And indeed, the degree of tissue regrowth and the repair of wounds with minimal scarring is so much greater in young children”
Insulin and oxytocin are examples of peptides familiar to most people; oxytocin is sometimes called the love hormone but that is not the best description.
“insulin, which is involved in regulating our blood sugar... is a peptide. Oxytocin, which is sometimes called the love hormone”
Today we are discussing peptides, and I will explain what a peptide is in a few moments.
“Today, we are discussing peptides.”